Related references
Note: Only part of the references are listed.Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease
Bernd Metzner et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2022)
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
Ying Liu et al.
BLOOD ADVANCES (2022)
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma
Zachery Halford et al.
ANNALS OF PHARMACOTHERAPY (2021)
CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma
Xiaoxi Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Victor E. Tedesco et al.
JOURNAL OF IMMUNOLOGY (2021)
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
Zhiling Yan et al.
FRONTIERS IN IMMUNOLOGY (2021)
CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
Jiaying Wu et al.
BLOOD CANCER JOURNAL (2021)
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Alejandrina Hernandez-Lopez et al.
FRONTIERS IN PHARMACOLOGY (2021)
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
Sylvain Lamure et al.
CANCERS (2021)
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas
Yang Cao et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Tianyi Wang et al.
CELL TRANSPLANTATION (2021)
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Andrew M. Evens et al.
BLOOD (2021)
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies
Na Wang et al.
BLOOD (2020)
High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
Sung-Won Kim et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy
Wilhelm Woessmann et al.
BLOOD (2020)
Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells
Wenqun Zhang et al.
BLOOD (2020)
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
Juan Du et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
Tao Wang et al.
IMMUNOTHERAPY (2020)
Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy
Jia Wei et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CAR T cells induce a complete response in refractory Burkitt Lymphoma
Abraham Avigdor et al.
BONE MARROW TRANSPLANTATION (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Burkitt lymphoma- a rare but challenging lymphoma
Carla Casulo et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)